Similarly, low baseline serum IGF-1 levels were associated with poor treatment response, PFS, and OS in patients who received anti-angiogenic therapy for advanced HCC [13]and those underwent curative treatment for early-stage HCC [14]. The gene discussed is IGF1; the disease is hepatocellular carcinoma.